A Distinct Structure Inside the Galactic Bar

We present the result of a near-infrared (J H Ks) survey along the Galactic plane, -10.5deg < l < +10.5deg and b=+1.0deg, with the IRSF 1.4m telescope and the SIRIUS camera. Ks vs. H-Ks color-magnitude diagrams reveal a well-defined population of red clump (RC) stars whose apparent magnitude peak changes continuously along the Galactic plane, from Ks=13.4 at l=-10deg to Ks=12.2 at l=+10deg after dereddening. This variation can be explained by the bar-like structure found in previous studies, but we find an additional inner structure at |l| < 4deg, where the longitude - apparent magnitude relation is distinct from the outer bar, and the apparent magnitude peak changes by only 0.1 mag over the central 8deg. The exact nature of this inner structure is as yet uncertain.Comment: 8 pages, 4 figures. accepted by ApJ

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

[Background] Accelerated tumor growth during immunotherapy in pre-existing measurable lesions, hyperprogressive disease (HPD), has been reported. However, progression of non-measurable lesions and new lesions are frequently observed in patients with advanced gastric cancer (AGC). [Methods] This retrospective study involved AGC patients at 24 Japanese institutions who had measurable lesions and received nivolumab after ≥ 2 lines of chemotherapy. HPD was defined as a ≥ two-fold increase in the tumor growth rate of measurable lesions. The pattern of disease progression was classified according to new lesions in different organs and ascites appeared/increase of ascites. [Results] Of 245 patients, 147 (60.0%) showed progressive disease (PD) as the best response and 41 (16.7%) showed HPD during nivolumab monotherapy. There was no significant difference in overall survival (OS) between patients with HPD and those with PD other than HPD (median OS 5.0 vs 4.8 months; hazard ratio [HR] 1.0, 95% confidence interval [CI] 0.6–1.5; p = 1.0). Fifty-three patients developed new lesions in different organs and 58 had appearance/increase of ascites; these patients showed shorter OS than those without each of these features (median OS 3.3 vs 7.1 months, HR 1.8, 95% CI 1.2–2.7, p = 0.0031 for new lesions, and 3.0 vs 7.8 months, HR 2.6, 95% CI 1.8–3.8, p < 0.0001 for ascites). Thirty-one patients who had both features showed the worst prognosis (median OS 2.6 months). [Conclusions] New lesions in different organs and appearance/increase of ascites, rather than the original definition of HPD, are the patterns of disease progression associated with poor prognosis in AGC patients receiving nivolumab whose best response was PD

Changes in expression levels of ERCC1, DPYD, and VEGFA mRNA after first-line chemotherapy of metastatic colorectal cancer: results of a multicenter study

Our previous study showed that administering oxaliplatin as first-line chemotherapy increased ERCC1 and DPD levels in liver colorectal cancers (CRCs) metastases. Second, whether the anti-VEGF monoclonal antibody bevacizumab alters tumoral VEGFA levels is unknown. We conducted this multicenter observational study to validate our previous findings on ERCC1 and DPD, and clarify the response of VEGFA expression to bavacizumab administration. 346 CRC patients with liver metastases were enrolled at 22 Japanese institutes. Resected liver metastases were available for 175 patients previously treated with oxaliplatin-based chemotherapy (chemotherapy group) and 171 receiving no previous chemotherapy (non-chemotherapy group). ERCC1, DPYD, and VEGFA mRNA levels were measured by real-time RT-PCR. ERCC1 mRNA expression was significantly higher in the chemotherapy group than in the non-chemotherapy group (P = 0.033), and were significantly correlated (Spearman\u27s correlation coefficient = 0.42; P < 0.0001). VEGFA expression level was higher in patients receiving bevacizumab (n = 51) than in those who did not (n = 251) (P = 0.007). This study confirmed that first-line oxaliplatin-based chemotherapy increases ERCC1 and DPYD expression levels, potentially enhancing chemosensitivity to subsequent therapy. We also found that bevacizumab induces VEGFA expression in tumor cells, suggesting a biologic rationale for extending bevacizumab treatment beyond first progression

ドジョウ カンソウ ショリ オヨビ ヒカリ ハンシャ シート ノ フセツ ガ カシス(Ribes nigrum L.)ノ カジツ ヒンシツ ビタミンC ガンリョウ オヨビ コウサンカノウ ニ オヨボス エイキョウ

ポット植えしたカシス`ラジアント\u27を,かん水量を制限した乾燥土壌で栽培した。その結果,十分にかん水した場合と比較して果実が小型化し,滴定酸度は上昇し,ビタミンC含量は増加傾向を示した。屈折計示度および抗酸化能(H-ORAC)は変化しなかった。また,カシス`ネービス\u27を,株の周辺に光反射シートを敷設して栽培した。この際,かん水は十分量を与えた。その結果,無処理の場合と比較して屈折計示度および滴定酸度は変化しなかったが,ビタミンC含量が増加し,抗酸化能は上昇傾向を示した。以上のことから,土壌乾燥処理や光反射シートの利用によってカシス果実の栄養および機能性を向上させ得ることが示された。Potted plants of the blackcurrant cultivar `Radiant\u27 were subjected to soil drying with limited irrigation. The treatment decreased fruit size, increased titratable acidity, and tended to increase vitamin C content in fruits, as compared with sufficiently irrigated plants. There was no difference in soluble solid content and antioxidant capacity (evaluated using the hydrophilic-oxygen radical absorbance capacity (H-ORAC) method) between the treated and control plants. Potted plants of the blackcurrant cultivar `Nevis\u27 were subjected to mulching culture by using a light-reflecting sheet. In this experiment, both treated and control plants were sufficiently watered. The soluble solid content and titratable acidity of the treated fruits were similar to those of the control fruits, while vitamin C content of the treated fruits was higher and antioxidant capacity of the treated fruits tended to increase as compared with the control fruits. These results indicate that soil drying and a light-reflecting sheet are capable of increasing the nutritional quality and functional components of blackcurrant fruits

Quantitative Analysis of Serum Procollagen Type I C-Terminal Propeptide by Immunoassay on Microchip

BACKGROUND: Sandwich enzyme-linked immunosorbent assay (ELISA) is one of the most frequently employed assays for clinical diagnosis, since this enables the investigator to identify specific protein biomarkers. However, the conventional assay using a 96-well microtitration plate is time- and sample-consuming, and therefore is not suitable for rapid diagnosis. To overcome these drawbacks, we performed a sandwich ELISA on a microchip. METHODS AND FINDINGS: The microchip was made of cyclic olefin copolymer with straight microchannels that were 300 µm wide and 100 µm deep. For the construction of a sandwich ELISA for procollagen type I C-peptide (PICP), a biomarker for bone formation, we used a piezoelectric inkjet printing system for the deposition and fixation of the 1st anti-PICP antibody on the surface of the microchannel. After the infusion of the mixture of 2.0 µl of peroxidase-labeled 2nd anti-PICP antibody and 0.4 µl of sample to the microchannel and a 30-min incubation, the substrate for peroxidase was infused into the microchannel; and the luminescence intensity of each spot of 1st antibody was measured by CCD camera. A linear relationship was observed between PICP concentration and luminescence intensity over the range of 0 to 600 ng/ml (r(2) = 0.991), and the detection limit was 4.7 ng/ml. Blood PICP concentrations of 6 subjects estimated from microchip were compared with results obtained by the conventional method. Good correlation was observed between methods according to simple linear regression analysis (R(2) = 0.9914). The within-day and between-days reproducibilities were 3.2-7.4 and 4.4-6.8%, respectively. This assay reduced the time for the antigen-antibody reaction to 1/6, and the consumption of samples and reagents to 1/50 compared with the conventional method. CONCLUSION: This assay enabled us to determine serum PICP with accuracy, high sensitivity, time saving ability, and low consumption of sample and reagents, and thus will be applicable to clinic diagnosis

Photonic and Iontronic Sensing in GaInAsP Semiconductor Photonic Crystal Nanolasers

The GaInAsP semiconductor photonic crystal nanolaser operates at room temperature by photopumping and emits near-infrared light at a wavelength longer than 1.3 μm. Immersion of the nanolaser in a solution causes its laser characteristics to change. Observation of this phenomenon makes it possible to perform biosensing without a fluorescent label or a chromogenic substrate. The most common phenomenon between many photonic sensors is that the resonance wavelength reflects the refractive index of attached media; an index change of 2.5 × 10−4 in the surrounding liquid can be measured through an emission wavelength shift without stabilization. This effect is applicable to detecting environmental toxins and cell behaviors. The laser emission intensity also reflects the electric charge of surface ions. The intensity varies when an electrolyte or a negatively charged deoxyribonucleic acid (DNA), which is positively or negatively charged in water, is accumulated on the surface. This effect allows us to detect the antigen-antibody reaction of a biomarker protein from only the emission intensity without any kind of spectroscopy. In detecting a small amount of DNA or protein, a wavelength shift also appears from its concentration that is 2–3 orders of magnitude lower than those of the conventional chemical methods, such as the enzyme-linked immuno-solvent assay. It is unlikely that this wavelength behavior at such low concentrations is due to the refractive index of the biomolecules. It is observed that the electric charge of surface ions is induced by various means, including plasma exposure and an electrochemical circuit shifting the wavelength. This suggests that the superhigh sensitivity is also due to the effect of charged ions. Thus, we call this device an iontronic photonic sensor. This paper focuses on such a novel sensing scheme of nanolaser sensor, as an example of resonator-based photonic sensors, in addition to the conventional refractive index sensing